Thermo Fisher Scientific Ataxin 1 Polyclonal Antibody

Applications

Western Blot (WB)

• Tested Dilution: 1:500–1:3,000
• Publications: -

Product Specifications

Product Specific Information

• Positive Control: Neuro2A, C8D30, NIH-3T3, Raw264.7
• Predicted Reactivity: Rat (100%)
• Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.

Target Information

The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem, and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I–III.
ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4, and 6, assigned to different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII, often referred to as the "pure" cerebellar syndrome (SCA5), are more homogeneous.
Several SCA genes contain CAG repeats in their coding regions, and expansion of these repeats produces elongated polyglutamine tracts in the corresponding proteins. The expanded repeats are unstable and tend to increase in size across generations.
This locus has been mapped to chromosome 6, and the diseased allele contains 41–81 CAG repeats (normal: 6–39), associated with spinocerebellar ataxia type 1 (SCA1). At least two transcript variants encoding the same protein have been identified.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.